Abstract 13611: Adherence to Non-VKA Oral Anticoagulant Medications Based on the Pharmacy Quality Alliance Measure
Introduction: CMS Star Ratings help inform beneficiaries about the performance of health and drug plans. Medication adherence and other pharmacy measures are currently weighted at nearly half of a Part D plan’s Star Ratings. Two, 3, 4 and 5 Star Ratings are based on achievement of adherence threshold levels (e.g. 74%, 79%, 82%, and 85% for oral diabetes medications). Including the adherence to non-VKA oral anticoagulant (NOACs) as a measure in the Star Ratings program may increase a plan’s incentives to improve patient adherence.
Objective: To assess the adherence to medication of patients who used the NOACs rivaroxaban, dabigatran, or apixaban in 2014 based on the Pharmacy Quality Alliance (PQA) adherence measure.
Methods: Healthcare claims from the Humana database between 07/2013 and 12/2014 were analyzed. Adult patients with ≥2 dispensings of NOAC agents in 2014, at least 180 days apart between two NOAC dispensings in 2014 (a criterion to include chronic users), with >60 days of supply, and ≥180 days of continuous enrollment prior to the index NOAC were identified. PQA measure was calculated as the percentage of patients who had a proportion of days covered (PDC) ≥80%. PQA measure was compared between rivaroxaban and each of the other two groups using chi squared tests. Multivariate logistic regression analyses were also conducted adjusting for baseline confounders.
Results: A total of 11,095 rivaroxaban, 6,548 dabigatran, and 3,532 apixaban users were identified. Based on the PQA adherence measure (PDC ≥0.8), a significantly higher proportion of rivaroxaban users (72.7%) was found to be adherent compared to dabigatran (67.2%: p<.001) and apixaban (69.5%: p<.001) users. Compared to apixaban users, the adjusted likelihood of being adherent was significantly higher for rivaroxaban users (unadjusted OR: 1.17, p-value<.001; adjusted OR: 1.20, p-value<.001), and significantly lower for dabigatran users (unadjusted OR: 0.90, p-value=0.019; adjusted OR: 0.85, p-value<.001).
Conclusion: Using the PQA’s adherence measure, rivaroxaban users were found to have a significantly higher adherence compared to apixaban and dabigatran users. Healthcare providers should consider the impact of anticoagulation selection on their ability to achieve quality metrics.
Author Disclosures: C. McHorney: Research Grant; Significant; Janssen Scientific Affairs, LLC. C. Crivera: Research Grant; Modest; N/A. Other Research Support; Modest; N/A. Speakers Bureau; Modest; N/A. Honoraria; Modest; N/A. Expert Witness; Modest; N/A. Consultant/Advisory Board; Modest; N/A. Other; Modest; N/A. Employment; Significant; Johnson and Johnson. Ownership Interest; Significant; Owns in excess of $10,000 JNJ stock. F. Laliberté: Research Grant; Significant; Janssen Scientific Affairs, LLC. W.W. Nelson: Employment; Significant; Janssen Scientific Affairs, LLC. G. Germain: Research Grant; Significant; Janssen Scientific Affairs, LLC. B.K. Bookhart: Employment; Significant; Janssen Scientific Affairs, LLC. S. Martin: Employment; Significant; Janssen Scientific Affairs. J. Schein: Employment; Significant; Janssen Scientific Affairs, LLC. P. Lefebvre: Research Grant; Significant; Janssen Scientific Affairs, LLC. S. Deitelzweig: Research Grant; Significant; Janssen Scientific Affairs, LLC.
- © 2015 by American Heart Association, Inc.